Mounjaro injection uses: what this medicine actually does (and what it doesn't)

The biggest misconception: Mounjaro is not just a diabetes drug you can use off-label for weight loss

Many people arrive at this topic assuming tirzepatide was originally a diabetes medicine that doctors later started using informally for weight loss. That's understandable (it's the story of several older GLP-1 medicines) but it's not accurate for Mounjaro. In the UK, tirzepatide holds two separate, fully licensed indications: type 2 diabetes management and weight management alongside a reduced-calorie diet and increased activity. These are distinct licences, not a single approval being stretched.

The weight-management licence covers adults with a BMI of 30 or above, or 27 and above when at least one weight-related condition is present, high blood pressure, prediabetes, dyslipidaemia, or obstructive sleep apnoea, among others. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Crucially, BMI alone doesn't determine whether a prescription is appropriate; the prescriber reviews the whole clinical picture. As the NHS tirzepatide medicines page explains, tirzepatide is a prescription-only medicine, and suitability is assessed individually.

The practical implication: if you've read that Mounjaro is "a diabetes jab" being repurposed, that framing doesn't apply in the UK. Both uses are on the label.

How Mounjaro actually works in the body, and why dual action matters for weight

Tirzepatide's mechanism is what makes it distinct. It activates two receptors at once: the GLP-1 (glucagon-like peptide-1) receptor, which reduces appetite and slows the rate at which the stomach empties, and the GIP (glucose-dependent insulinotropic polypeptide) receptor, which plays a complementary role in energy regulation and fat metabolism. No other weight-management medicine licensed in the UK works across both pathways.

The practical effect is a significant reduction in appetite and caloric intake, which is why Mounjaro is used alongside (not instead of) dietary changes and increased physical activity. The injection itself doesn't burn fat directly; it changes the hormonal signals that govern how hungry you feel and how quickly you feel full. This is also why the starting dose of 2.5 mg exists: it gives the body time to adapt before the dose is increased, reducing the chance of early nausea. For more detail on the injection format itself, the Mounjaro KwikPen guide covers what the pen looks like and how it's structured.

If you're interested in how tirzepatide compares with semaglutide as a class, the tirzepatide injection uses page sets out the broader clinical context.

What clinical trials showed about weight-management outcomes

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity who did not have type 2 diabetes. Over 72 weeks, participants on the 15 mg dose saw an average body-weight reduction of around 20 to 21 percent. That's a larger average reduction than any previously approved weight-management medicine in the UK at the time. NICE reviewed this evidence in its technology appraisal TA1026 and recommended tirzepatide for eligible adults, subject to defined BMI and comorbidity criteria.

A few important caveats. First, trial results are averages across a study population, individual outcomes vary, and no prescriber can guarantee a specific amount of weight loss. Second, NICE's recommendation for NHS use applies to people with a BMI of 35 or above plus at least one weight-related comorbidity; private prescribing follows the licensed SmPC criteria, which are somewhat broader. Third, the 6-month checkpoint matters: if someone doesn't achieve at least 5 percent weight loss after six months at the highest tolerated dose, continuing treatment is reviewed.

If the cost of treatment is part of your thinking, the Mounjaro cost breakdown explains how UK private pricing works, including what a single transparent fee should cover.

Side effects, safety monitoring, and what to watch for

The side-effect profile of Mounjaro is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion, and reflux are the most commonly reported. These tend to be most noticeable after a new pen is started or after a dose increase, many people find them settle within a couple of weeks. Taking the injection at a consistent time each week and staying well hydrated both help.

Two safety points deserve clear mention. Acute pancreatitis is a known but infrequent serious risk: severe stomach pain that spreads to the back, with or without vomiting, warrants urgent medical attention. The MHRA flagged this specifically in a January 2026 Drug Safety Update covering GLP-1 medicines. Separately, because Mounjaro can slow gastric emptying, women using oral contraceptives should add a barrier method for the first four weeks of treatment and for four weeks after each dose increase, absorption of the pill can be reduced during that period. NHS guidance recommends considering transdermal HRT (patches or gels) for the same reason.

If you're preparing for your first dose and want to understand more about the Mounjaro injection itself, including how it's supplied and what to expect when it arrives, that page is a useful starting point. For a practical walk-through of the technique, our guide to how to use the Mounjaro injection covers site rotation, needle handling, and storage. For sharps disposal after each pen, a 1-litre sharps container is the standard safe option.

Our prescribers review every consultation personally, a real clinician reads your answers the same day. If you have questions about your specific situation, start your free consultation and they'll assess whether Mounjaro is the right fit for you.